These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33877602)

  • 1. Fragment Screening by NMR.
    Davis BJ
    Methods Mol Biol; 2021; 2263():247-270. PubMed ID: 33877602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds.
    Yu JL; Chen TT; Zhou C; Lian FL; Tang XL; Wen Y; Shen JK; Xu YC; Xiong B; Zhang NX
    Acta Pharmacol Sin; 2016 Jul; 37(7):984-93. PubMed ID: 27238211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR-Fragment Based Virtual Screening: A Brief Overview.
    Singh M; Tam B; Akabayov B
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29370102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR screening and hit validation in fragment based drug discovery.
    Campos-Olivas R
    Curr Top Med Chem; 2011; 11(1):43-67. PubMed ID: 20809889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR spectroscopy: the swiss army knife of drug discovery.
    Horst R; Farley KA; Kormos BL; Withka JM
    J Biomol NMR; 2020 Nov; 74(10-11):509-519. PubMed ID: 32617727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery.
    Wu B; Zhang Z; Noberini R; Barile E; Giulianotti M; Pinilla C; Houghten RA; Pasquale EB; Pellecchia M
    Chem Biol; 2013 Jan; 20(1):19-33. PubMed ID: 23352136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-Based Ligand Designing.
    Katiyar SP; Malik V; Kumari A; Singh K; Sundar D
    Methods Mol Biol; 2018; 1762():123-144. PubMed ID: 29594771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical aspects of NMR-based fragment screening.
    Lepre CA
    Methods Enzymol; 2011; 493():219-39. PubMed ID: 21371593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand and Target Discovery by Fragment-Based Screening in Human Cells.
    Parker CG; Galmozzi A; Wang Y; Correia BE; Sasaki K; Joslyn CM; Kim AS; Cavallaro CL; Lawrence RM; Johnson SR; Narvaiza I; Saez E; Cravatt BF
    Cell; 2017 Jan; 168(3):527-541.e29. PubMed ID: 28111073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragments: where are we now?
    Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
    Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fast and Efficient Fragment-Based Lead Generation by Fully Automated Processing and Analysis of Ligand-Observed NMR Binding Data.
    Peng C; Frommlet A; Perez M; Cobas C; Blechschmidt A; Dominguez S; Lingel A
    J Med Chem; 2016 Apr; 59(7):3303-10. PubMed ID: 26964888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMR quality control of fragment libraries for screening.
    Sreeramulu S; Richter C; Kuehn T; Azzaoui K; Blommers MJJ; Del Conte R; Fragai M; Trieloff N; Schmieder P; Nazaré M; Specker E; Ivanov V; Oschkinat H; Banci L; Schwalbe H
    J Biomol NMR; 2020 Nov; 74(10-11):555-563. PubMed ID: 32533387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.